# US 2018/0021559 A1 · Microdevice and method for transdermal delivery and sampling of active substances

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021559 A1
- Document ID: US20180021559A1
- Status: Published application
- Kind: A1
- Application number: 15/714,628
- Filed: 2017-09-25
- Published: 2018-01-25
- Earliest claimed: 2006-12-22
- Assignees: Nanomed Skincare, Inc.
- Applicants: Nanomed Skincare, Inc.
- Inventors: Bai XU
- Web page: https://patentgrep.com/patent/US20180021559A1

## CPC

- A61M 37/0092: {using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 38/21: Interferons {[IFN]}
- A61M 37/0015: {by using microneedles}
- A61N 1/303: {Constructional details (electrodes for external use A61N1/0428)}
- A61P 35/00: Antineoplastic agents
- A61M 2037/0007: {having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/003: {having a lumen}
- A61M 2037/0046: {Solid microneedles}
- A61M 2037/0053: {Methods for producing microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A system and method of using a high-aspect ratio microdevice for treating, preventing or ameliorating a medical condition is provided.

## Claims

### Claim 1

A method of delivering an agent, or a combination of agents, for a medical condition to a mammal, comprising
applying an applicator comprising a microdevice to cause the microdevice to contact an area of skin of the mammal to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the prepared area of skin and removing the applicator and microdevice from the skin immediately after the microdevice has penetrated the skin,
applying a wet formulation comprising the agent to the area of skin being prepared either before or after the microdevice has generated the plurality of nanopores or nanochannels in the prepared area of skin,
subsequently applying an occlusive layer over the agent and directly on the prepared area of skin such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice from the skin, and
causing an effective amount of agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum at a rate percent penetration that is higher than the rate of percent penetration if no nanopores or nanochannels are present.

### Claim 2 (depends on 1)

The method of claim 1, wherein causing an effective amount of the agent to deliver to the patient comprises:
allowing the agent to diffuse into the patient from the formulation, or
driving the agent into the patient by applying a driving force to the formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein agent is encapsulated within elastic liposomes.

### Claim 4 (depends on 1)

The method of claim 1, wherein the wet formulation does not comprise elastic liposomes.

### Claim 5 (depends on 3)

The method of claim 3, wherein the elastic liposome comprises liposome nanoparticles.

### Claim 6 (depends on 2)

The method of claim 2, wherein the driving force is selected from iontophoresis, sonophoresis, radiofrequency (RF), heat gradient or a combination of these.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mammal has a medical condition,
wherein the agent is a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and
wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, meningococcus, and cholera.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent is a pain relieving agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the medical condition is chronic back pain.

### Claim 10 (depends on 8)

The method of claim 8, wherein the medical condition is a cancer.

### Claim 11 (depends on 8)

The method of claim 8, wherein the medical condition is pre-surgery pain management, operation room pain management or post-surgery pain management.

### Claim 12 (depends on 8)

The method of claim 8, wherein the pain relieving agent is lidocaine, tetracaine, dyclonine or a combination thereof, and
wherein the formulation is a topical or systemic delivery formulation selected from lotion, cream, gel patch, ointment or skin patch comprising lidocaine, tetracaine, dyclonine or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mammal is a human and wherein the medical condition is cancer pain, post-surgery pain and lower back pain.

### Claim 15 (depends on 1)

The method of claim 1, wherein the formulation is a wet skin patch.

### Claim 16

A kit for delivering an agent to a mammal, comprising:
a microdevice comprising a structure selected from microneedles, microblades, microknives, and combinations thereof;
a wet formulation comprising a bioactive agent;
a mechanism to provide for a driving force to the microdevice; and
an occlusive layer.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the driving force is ultrasound, iontophoresis, radio frequency or heat gradient.

### Claim 18 (depends on 16)

The kit of claim 16, further comprising
an applicator of the microdevice for applying the microdevice to an area of skin of a mammal.

### Claim 19 (depends on 16)

The kit of claim 16, further comprising
a driving force mechanism for driving the bioactive agent to transport through the stratum corneum of the area of skin into the mammal.

### Claim 20 (depends on 16)

The kit of claim 16, wherein the mammal has a medical condition,
wherein the agent is a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and
wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.

### Claim 21 (depends on 16)

The kit of claim 16, wherein the formulation comprises elastic liposomes encapsulating the agent.

### Claim 22 (depends on 16)

The kit of claim 16, wherein the formulation does not comprises elastic liposomes.

### Claim 23 (depends on 21)

The kit of claim 21, wherein the elastic liposome comprises deformable nanoparticles.

### Claim 24 (depends on 16)

The kit of claim 16, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

### Claim 25 (depends on 16)

The kit of claim 16, wherein the driving force mechanism comprises ultrasound, or radio frequency, heat gradient or iontophoresis device.

### Claim 26 (depends on 16)

The kit of claim 16, wherein the agent is a pain relieving agent.

### Claim 27 (depends on 26)

The kit of claim 26, wherein the pain relieving agent is lidocaine, tetracaine, dyclonine or a combination of thereof, and
wherein the formulation is lotion, cream, gel patch, ointment or skin patch comprising lidocaine, tetracaine, dyclonine or a combination thereof.

### Claim 28 (depends on 16)

The kit of claim 16, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

### Claim 29 (depends on 16)

The kit of claim 16, wherein the applicator is a mechanical applicator.

### Claim 30 (depends on 16)

The kit of claim 16, wherein the formulation is a wet skin patch.
